PRTC — Puretech Health Cashflow Statement
0.000.00%
- £301.68m
- -£64.62m
- $3.33m
Annual cashflow statement for Puretech Health, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 366 | 4.57 | -62.7 | -37.1 | -66.6 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | -599 | -112 | -72.8 | -146 | -74.3 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 16.2 | -30.8 | -30.1 | -4.68 | 30.1 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Net Change in Other Assets & Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -98.2 | -132 | -158 | -179 | -106 |
Capital Expenditures | -12.5 | -5.42 | -5.66 | -2.18 | -0.245 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 76.2 | 370 | 203 | -105 | 69.2 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 63.7 | 364 | 197 | -107 | 69 |
Financing Cash Flow Items | -1.28 | -12.9 | -14.1 | -0.041 | 100 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 49.9 | 38.9 | 22.7 | -29.8 | 78.1 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 15.3 | 272 | 61.8 | -316 | 41.2 |